Abstract
Immunotherapy is a treatment modality which meets considerable interest. Manipulation of the immune system is based, firstly, on our steadily increasing insight into the various cellular and humoral entities involved in an immune response and, secondly, from the availability of an array of monoclonal antibodies and recombinant cytokines, which offer the possibility to induce and/or modify immune activities.
This work has been supported by grant GUKC 89-07 from the Dutch Cancer Society.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg SA, Lotze MT, Muul LM, et al. Observation on the systemic administration of autologous lymphokine-activated killer cells and rIL-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.
West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immune therapy of advanced cancer. N Engl J Med 1987;316:898–905.
Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cell cancer treated with interleukin-2 and lymphokine activated killer cells. Ann Int Med 1988;100:518–23.
Sleijfer DTh, Janssen RAJ, Willemse PHB, et al. Low dose regimen of interleukin-2 for metastatic carcinoma. Lancet 1990;335:1522–3.
Stein RC, Malkovska V, Morgan S, et al. The clinical effects of prolonged treatment of patients with advanced cancer with low dose subcutaneous interleukin-2. Brit J Cancer 1991;63:275–8.
Fraker DL, Langstein HH, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med 1989;170:1015–20.
Gallinger S, Hoshin DW, Mullen JB, Wong AH, Roder JC. Comparison of cellular immunotherapy and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastasis in C57B1/6 mice. Cancer Res 1990;50:2476–80.
Alexander J, Rayman P, Edinger M, et al. TIL from renal cell carcinoma: Restimulation with tumor influences proliferation and cytolytic activity. Int J Cancer 1990;45: 119–24.
Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988;6:409–24.
Wolfel T, Klehman E, Mueller C, et al. Lysis of human melanoma cells by autologous cytolytic T-cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170: 797–810.
Sette A, Grey HM. Chemistry of peptide interactions with MHC proteins. Curr Opin Immunol 1992;4:79–86.
Mach JP, Pelegrin A, Buchegger F. Imaging and therapy with monoclonal antibodies in non-haematopoietic tumors. Curr Opin Immunol 1991;3:685–93.
Goldenberg DM, Schlom J. The coming of age of cancer radioimmunoconjugates. Immunol Today 1993;14:5–7.
Meuer SC, Schlossman SF, Reinhertz EL. Clonal analysis of human cytotoxic T-lymphocytes: T4 and T8 effector cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci USA 1982;79:4395–9.
Spits H, Yssel H, Leeuwenberg J, de Vries JE. Antigen-specific T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol 1985;15:88–91.
Staertz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628–31.
Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic Tlymphocytes. Eur J Immunol 1987;17:105.
De Leij L, Postmus PE, Poppema S, Elema J, The TH. The use of monoclonal antibodies for the pathological diagnosis of lung cancer. In: Hansen HH (ed). Lung Cancer: Basic and clinical aspects. Martinus Nijhoff Publishers Boston/Dordrecht/Lancaster 1986:31–48.
De Lau WBM, van Loon AE, Heije K, Valerio D, Bast EJE. Production of hybrid hybridomas based on HAT-s/neomycin-r double mutants. J Immunol Methods 1989; 146:906–16.
Spurr NK, Durbin H, Sheet D, et al. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUA-1. Int J Cancer 1986;38:631–6.
Herlyn D, Herlyn M, Ross AH, et al. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 1984;73:157–67.
Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicity of 1251-labelled monoclonal antibody 17-1A in human cancer cells. Cancer Res 1989,49:2952–8.
De Leij L, de Jonge MWA, ter Haar J, et al. Bispecific monoclonal antibody (Biab)-retargeted cellular therapy for local treatment of cancer patients. In: Crommelin DJA, Schellekens H (eds). From clone to clinic. Kluwer Academic Publishers 1990:159–65.
Elias MK, de Leij L, Smit Sibinga CTh, Das PC. Killing capacity of LAK cell transduced lymphocytes harvested by Haemonetics V50 lymphosurge technique. In: Rock G (ed). Apheresis. Progress in clinical and biological research. Vol. 337. New York: Alan R. Liss 1989:469–76.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
de Leij, L. et al. (1993). Immune Targeting of T-Lymphocytes. In: Sibinga, C.T.S., Das, P.C., The, T.H. (eds) Immunology and Blood Transfusion. Developments in Hematology and Immunology, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3094-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3094-7_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6352-1
Online ISBN: 978-1-4615-3094-7
eBook Packages: Springer Book Archive